Edgewise Therapeutics, Inc. (EWTX)

NASDAQ: EWTX · IEX Real-Time Price · USD
14.59 0.05 (0.34%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap719.23M
Revenue (ttm)n/a
Net Income (ttm)-36.46M
Shares Out49.30M
EPS (ttm)-1.44
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume220,330
Open14.24
Previous Close14.54
Day's Range14.24 - 15.07
52-Week Range13.19 - 40.49
Betan/a
AnalystsStrong Buy
Price Target32.50 (+122.8%)
Earnings DateNov 8, 2021

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colora...

IndustryBiotechnology
IPO DateMar 26, 2021
Employees30
Stock ExchangeNASDAQ
Ticker SymbolEWTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for EWTX stock is "Strong Buy." The 12-month stock price forecast is 32.50, which is an increase of 122.76% from the latest price.

Price Target
$32.50
(122.76% upside)
Analyst Consensus: Strong Buy

News

Edgewise Therapeutics Shares Jump After Positive Data On Becker Muscular Dystrophy Study

Edgewise Therapeutics Inc (NASDAQ: EWTX) posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as...

2 weeks ago - Benzinga

Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Bec...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

2 weeks ago - Business Wire

Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (B...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

1 month ago - Business Wire

Edgewise Therapeutics to Participate at Evercore ISI 4th Annual HEALTHCONx Conference on December 2

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

2 months ago - Business Wire

Edgewise Therapeutics Reports Third Quarter 2021 Financial Results

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

2 months ago - Business Wire

Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Stud...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatm...

2 months ago - Business Wire

Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...

4 months ago - Business Wire

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

5 months ago - Business Wire

Edgewise Therapeutics Reports Second Quarter 2021 Financial Results

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

5 months ago - Business Wire

Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

5 months ago - Business Wire

Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skele...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscl...

6 months ago - Business Wire

Losers Outnumber Gainers in Biotech IPOs This Year

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Other symbols:DBTXRXRXTAK
7 months ago - GuruFocus

Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

7 months ago - Business Wire

Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

8 months ago - Business Wire

Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

8 months ago - Business Wire

Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...

8 months ago - Business Wire

2 Juicy Biotech Stocks to Consider Buying Right Now

They're both innovating in attractive areas where there's no competition on the radar.

Other symbols:HGEN
9 months ago - The Motley Fool

Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option t...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

9 months ago - Business Wire

Edgewise Therapeutics Announces Pricing of Initial Public Offering

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscl...

9 months ago - Business Wire